Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY27 results · Apr–Jun 2026
Bliss GVS Pharma reported revenue from operations of ₹285.58 crore (up 37.6% from Q1 FY26) and net profit of ₹51.37 crore (up 15.8% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 285.58 | 207.47 | +37.6% | 256.99 | +11.1% |
| Other income | 9.60 | 35.45 | −72.9% | 11.16 | −14.0% |
| Total income | 295.18 | 242.92 | +21.5% | 268.15 | +10.1% |
| Profit before tax | 75.48 | 63.11 | +19.6% | 44.95 | +67.9% |
| Net profit for the period | 51.37 | 44.36 | +15.8% | 37.00 | +38.8% |
| Attributable to shareholders of the company | 50.10 | 43.04 | +16.4% | 35.58 | +40.8% |
| EPS, basic (₹) | 4.73 | 4.08 | +15.9% | 3.37 | +40.4% |
| Net margin (%) | 18.0 | 21.4 | 14.4 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 221.59 | 163.36 | +35.6% | 211.54 | +4.7% |
| Other income | 8.76 | 10.59 | −17.3% | 9.30 | −5.8% |
| Total income | 230.35 | 173.96 | +32.4% | 220.84 | +4.3% |
| Profit before tax | 51.21 | 30.56 | +67.6% | 44.15 | +16.0% |
| Net profit for the period | 38.62 | 21.05 | +83.4% | 32.42 | +19.1% |
| EPS, basic (₹) | 3.65 | 2.00 | +82.5% | 3.06 | +19.3% |
| Net margin (%) | 17.4 | 12.9 | 15.3 |
Consolidated
- Filed with BSE
- 12 Aug 2026, 19:42 IST
- Board meeting
- 12 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2026, 19:42 IST
- Board meeting
- 12 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE